Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Johnson & Johnson stock slipped Tuesday, even after the company reported first-quarter earnings that surpassed expectations ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

In an interview with conservative commentator Benny Johnson, the senator said he knew both would be considered conspiracy theorists.

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an ...

Cheeseheads and cheesecakes join the punchlines and headlines, and an enthusiastic audience gets a mild scolding for slipping past the censors. Temporarily.

a treatment for bipolar disorder and depression. Management said they now expect sales of $92 billion this year, up from a previous forecast of $91.3 billion. Johnson & Johnson’s cash flow.

The typical slot for the sketch show's political comedy tore into Donald Trump 's widespread tariffs, with James Austin Johnson's take on the president predicting that his plan would "Make America ...

In other recent news, Johnson & Johnson has completed the acquisition ... division with new treatments for schizophrenia and bipolar depression. The acquisition is expected to contribute ...